Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. BioNTech SE Sponsored ADR (BNTX) is a stock that can certainly grab the attention of ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

The top financial leader at Thermo Fisher Scientific Inc. plans to retire from the company in 2026 after more than a decade ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a ...

BioNTech's COVID-19 vaccine on one's eye, which could lead an indivual to permanent vision loss. Read on... TheHealthSite.com ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...

BioNTech (BNTX-1.19%) is the lesser-known member of the pair -- which also includes Pfizer -- that developed and marketed Comirnaty, one of the leading coronavirus vaccines on the market.

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that ...

BioNTech will pay OncoC4 $200 million up front and get global rights to its drug. Privately held OncoC4 could earn milestone payments, plus royalties if the research leads to a commercialized product.

Moderna is suing fellow vaccine developers Pfizer and its German partner BioNTech, accusing it of infringing on patents related to mRNA technology used in their COVID-19 vaccine, the company ...